⌘K
Loading ticker…
Catalyst Pharmaceutical Inc. · Healthcare · Pharmaceutical Products
As of 2026-06-26, Catalyst Pharmaceutical Inc. (CPRX) has a 3-month relative strength percentile of 81 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 62. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 0.1%, relative volume 2.36×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 81, Market Stance is mixed at 47, A/D rating A
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
CPRX is in a stage 2 uptrend, week 11. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 4.0% / 27.4%.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
CPRX is held by 7 ETFs as of Mar 2026. Top owner: IJR at 0.19% weight, $172M notional. Top 3 carry $334M.
Top 7 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| IJRiShares Core S&P Small-Cap ETF | 0.19% | $172M |
| VTIVanguard Total Stock Market ETF | 0.00% | $92M |
| IWMiShares Russell 2000 ETF | 0.10% | $70M |
| XBIState Street SPDR S&P Biotech ETF | 0.76% | $56M |
| VXFVanguard Extended Market ETF | 0.04% | $32M |
| IWOiShares Russell 2000 Growth ETF | 0.19% | $23M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $4M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CPRX Jan avg: -4.71% median: -5.11% win: 50% σ: 12.63% n: 4 2022-04-12 → 2026-05-29 | CPRX Feb avg: 1.57% median: -0.01% win: 50% σ: 7.02% n: 4 2022-04-12 → 2026-05-29 | CPRX Mar avg: 5.33% median: 6.61% win: 75% σ: 4.08% n: 4 2022-04-12 → 2026-05-29 | CPRX Apr avg: -0.15% median: -3.98% win: 40% σ: 8.02% n: 5 2022-04-12 → 2026-05-29 | CPRX May avg: -2.35% median: 2.76% win: 60% σ: 15.34% n: 5 2022-04-12 → 2026-05-29 | CPRX Jun avg: -0.89% median: -3.42% win: 25% σ: 12.38% n: 4 2022-04-12 → 2026-05-29 (current) | CPRX Jul avg: 14.64% median: 7.10% win: 75% σ: 21.64% n: 4 2022-04-12 → 2026-05-29 | CPRX Aug avg: 11.93% median: 9.49% win: 75% σ: 16.21% n: 4 2022-04-12 → 2026-05-29 | CPRX Sep avg: -7.03% median: -4.78% win: 0% σ: 6.63% n: 4 2022-04-12 → 2026-05-29 | CPRX Oct avg: 7.97% median: 8.04% win: 100% σ: 1.43% n: 4 2022-04-12 → 2026-05-29 | CPRX Nov avg: 12.12% median: 13.17% win: 100% σ: 8.51% n: 4 2022-04-12 → 2026-05-29 | CPRX Dec avg: 5.42% median: 5.31% win: 50% σ: 10.06% n: 4 2022-04-12 → 2026-05-29 |